Acta obstetricia et gynecologica Scandinavica
-
Acta Obstet Gynecol Scand · Jan 2009
Prognostic markers for coexistent carcinoma in high-risk endometrial hyperplasia with negative D-score: significance of morphometry, hormone receptors and apoptosis for outcome prediction.
Hysterectomy represents the current routine therapy for high-risk endometrial precancers. More sophisticated methods are needed for treatment decision among women who want to preserve fertility and seriously ill patients. Among women diagnosed with high-risk hyperplasia, approximately 40% show signs of endometrial cancer in the hysterectomy specimen. Thus, more sophisticated methods are needed to select the women at risk. ⋯ Histomorphometry seems superior in predicting coexistent carcinoma in high-risk endometrial hyperplasia and should be considered for clinical use.
-
Acta Obstet Gynecol Scand · Jan 2009
Lumbopelvic pain associated with catastrophizing and fear-avoidance beliefs in early pregnancy.
To examine and compare levels of catastrophizing, fear-avoidance beliefs, physical ability, and health-related quality of life in women with and without lumbopelvic pain (LP and NLP) in early pregnancy. ⋯ It is important to consider exaggerated negative thoughts about pain experiences and fear-avoidance beliefs when treating women with LP during pregnancy and to be aware of the great impact lumbopelvic pain has on women's lives during early pregnancy.
-
To identify risk factors implicated in the development of periventricular leukomalacia (PVL) and to evaluate the possible association between PVL with neonatal morbidity. ⋯ This study revealed that preterm neonates born to mothers with PPROM or preeclampsia, as well as neonates who presented with hypocarbia or suffered from IVH, appeared to be at high risk for the development of PVL.
-
Acta Obstet Gynecol Scand · Jan 2009
Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
To report the results of ovarian cancer treatment, where a regimen of intravenous cyclophosphamide followed by intraperitoneal cisplatin or carboplatin was administered as second line treatment. ⋯ IP can be used in second line treatment of ovarian cancer, but six treatment cycles appear associated with worse results compared to four.